Skip to main content

ADvance II

Deep Brain Stimulation of the Fornix in patients with mild Alzheimer's disease

Sponsor
Functional Neuromodulation Ltd
Drug
Deep Brain Stimulation of the fornix
Countries

Information about the intervention that will be tested in the study

Administration

The intervention will be administered via a deep brain stimulation targeting the Fornix (a minimally invasive surgical method in which stimulation electrodes are implanted into the specific area of the brain named fornix).

Is the intervention already on the market for another medical condition?

No

Will all participants receive the same intervention?

Participants will be selected at random to either receive one of the following options:

  • Brain stimulation of the fornix
  • No brain stimulation.

Neither the participant nor their doctor will know if the person is receiving the brain stimulation or not.

Information about participating in the study

What are the researchers trying to find out?

The purpose of the study is to evaluate the safety and efficacy of Deep Brain Stimulation of the fornix in people with mild probable Alzheimer's disease.

How long will the study last?

12 months

What your involvement will entail?
  • Participants will be asked to complete a test that will assess their memory, orientation, judgment and problem solving, personal care and community affairs (this is a test called CDR-CB)
  • Participants will be also requested to complete some tests to evaluate impaired function and possible cognitive impairment (i.e. iADRS).

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?

To take part in the study, participants must:

  • Be 65 years old and older
  • Have a diagnosis of probable Alzheimer's disease according to the National Institute on Aging/Alzheimer's Association core clinical criteria
  • Have a score of 0.5 to 1 in the Clinical Dementia Rating-Global Score (CDR) at screening suggesting a questionable dementia or mild cognitive impairment
  • Have results of lumbar puncture (spinal tap) with findings consistent with a diagnosis of Alzheimer's disease
  • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration
  • Be a good surgical candidate for placement of a deep brain stimulator as judged by the clinical team
  • If the person is taking acetylcholinesterase inhibitors as an approved Alzheimer’s disease medication (i.e. donepezil, rivastigmine, galantamine) the dosing regimen must have been stable for at least 60 days prior to signing the consent form and must be stable during the 12-month control period of the study.
Who cannot participate in the study?

People cannot take part in the study if they have:

  • A total score >10 in the Neuropsychiatric Inventory test (NPI) or a score >4 in any NPI domain (a questionnaire used to assess behavioral domains). This would suggest that the person has severe behavioural disturbances
  • Suicidal behaviour in the opinion of the investigator
  • An unstable medical condition that may interfere with the safety, tolerability and/or study assessments (e.g. cardiac, respiratory disease, hallucinations, major depression, brain tumor)
  • Any contraindication to brain scans (due to having prostheses, implants, a pacemaker or claustrophobia)
  • Currently prescribed any non-Alzheimer’s disease medications, that may interfere with the safety, tolerability and/or study assessments
  • Ongoing participation in another clinical study.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

Clinicaltrials.gov identifier

NCT03622905

Study contact information

Kristen Drake kdrake@fxneuromod.com

Lisa Fosdick lfosdick@fxneuromod.com

Link to full text

https://www.clinicaltrials.gov/ct2/show/NCT03622905

The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on January 2023.

This document has been reviewed by a member of the European Working Group of People with Dementia.

 
Acknowledgement

Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.

Image
ctw_acknowledgment_2023